Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, placebo-controlled, pivotal trial of AM-111 (0.4 mg/mL) in patients suffering from acute profound hearing loss

Trial Profile

A Phase III, placebo-controlled, pivotal trial of AM-111 (0.4 mg/mL) in patients suffering from acute profound hearing loss

Planning
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Brimapitide (Primary)
  • Indications Sensorineural hearing loss
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2018 New trial record
    • 30 Aug 2018 According to an Auris Medical media release, the company had a Type C meeting with the U.S. Food and Drug Administration (FDA). The FDA has provided guidance regarding the endpoints, design of the trial, the planned sample size, statistical methodology and the regulatory path forward. This trial design also incorporates specific feedback provided by the European Medicines Agency (EMA) earlier this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top